If you got a question, look no further.
We post the most common questions
in our FAQ section.
Please fill in the form below to receive a Free Sample of the Report.
View: New investment reforms lifting restrictions on the foreign funding of medicine production willmake Myanmar an attractive market to international generic drugmakers. This is due to the opportunity ofsecuring a first-mover advantage in this frontier market, as well as being a result of rising medicineconsumption. Nonetheless, we highlight that there is significant political uncertainty in Myanmar with theupcoming 2015 elections which poses as a risk to investment.Headline Expenditure Projections¦ Pharmaceutical sales: MMK387.5bn (USD390mn) in 2014 to MMK457.3bn (USD440mn) in 2015;+18.0% in local currency terms and +10.8% in US dollar terms.¦ Healthcare Expenditure: MMK1,217.9bn (USD1.2bn) in 2014 to MMK1,388.7bn (USD1.3bn) in 2015;+14.0% in local currency terms and +7.1% in US dollar terms.
Industry View 7SWOT 9Industry Forecast 10Pharmaceutical Market Forecast 10Table: Pharmaceutical Sales, Historical Data And Forecasts (Myanmar 2011-2019) 11Healthcare Market Forecast 13Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Myanmar 2011-2019) 16Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Myanmar 2011-2019) 17Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Myanmar 2011-2019) 17Pharmaceutical Trade Forecast 18Table: Pharmaceutical Trade Data And Forecasts (Myanmar 2013-2019) 19Table: Pharmaceutical Trade Data And Forecasts local currency (Myanmar 2013-2019) 19Macroeconomic Forecasts 20Economic Activity 20Recent Stability A Confidence Booster 20Kyat Yet To Become Major Player In Economy 21Risks To Outlook 22Industry Risk Reward Ratings 23Asia Pacific Risk/Reward Index 23Myanmar Risk/Reward Index 29Rewards 29Risks 29Market Overview 31Industry Trends And Developments 32Epidemiology 32Communicable Diseases And Other Injuries 32Table: Leading Causes Of Morbidity And Mortality In 2010 33Non-Communicable Diseases 33Regulatory Development 35Regional Harmonisation 37Intellectual Property Regime 38Health Regulation 38Table: List Of Health And Health-Related Legislation 39Table: Series Of Revisions To Myanmar's EML 40Healthcare Outlook 40Recent Healthcare Developments 41Competitive Landscape 46Latest Company Developments 46Company Profile 49Fame Pharmaceutical 49Mega Lifesciences 51Demographic Forecast 54Table: Population Headline Indicators (Myanmar 1990-2025) 55Table: Key Population Ratios (Myanmar 1990-2025) 55Table: Urban/Rural Population & Life Expectancy (Myanmar 1990-2025) 56Table: Population By Age Group (Myanmar 1990-2025) 56Table: Population By Age Group % (Myanmar 1990-2025) 57Glossary 59Methodology 61Pharmaceutical Expenditure Forecast Model 61Healthcare Expenditure Forecast Model 61Notes On Methodology 62Risk/Reward Index Methodology 63Index Overview 64Table: Pharmaceutical Risk/Reward Index Indicators 64Indicator Weightings 65